Merck Reports Solid Second Quarter; Its Drug Pipeline Looks Promising
publication date: Jul 27, 2012
Merck reported solid second quarter results and indicated that progress in its pipeline remains strong. Though the firm will face patent expiration of its blockbuster Singulair in coming weeks, we think shares remain fairly valued.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.